NEW YORK (GenomeWeb) – Sygnis said it has greatly expanded its Asian distribution network with a trio of deals with PhileKorea, Pharma Tech Korea, and Axil Scientific covering South Korea and Singapore.

Sygnis has granted non-exclusive rights to promote, market, and sell all existing and future product lines. PhileKorea and Pharma Tech Korea's deals cover the South Korean market; Axil Scientific's deal is for the Singaporean market.

Financial and other terms of the agreements were not disclosed.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Researchers hope to tease out the signature effects that different carcinogens leave on the genome to determine their contributions to disease, Mosaic reports.

The Wall Street Journal looks into the cost of new gene therapies.

An Imperial College London-led team reports that it was able to use a gene drive to control a population of lab mosquitos.

In PNAS this week: genomic effects of silver fox domestication, limited effect of mitochondrial mutations on aging in fruit flies, and more.